| Chemotherapy-induced peripheral neurotoxicity: A multifaceted, still unsolved issue |
16 |
| Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathies |
15 |
| Platinum-induced peripheral neurotoxicity: From pathogenesis to treatment |
14 |
| Small-fiber neuropathy: Expanding the clinical pain universe |
10 |
| Immune checkpoint inhibitors-induced neuromuscular toxicity: From pathogenesis to treatment |
9 |
| Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy |
9 |
| Peripheral nervous system involvement in lymphomas |
8 |
| Rituximab in chronic inflammatory demyelinating polyradiculoneuropathy with associated diseases |
8 |
| Overview and critical revision of clinical assessment tools in chemotherapy-induced peripheral neurotoxicity |
8 |
| Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: From pathogenesis to treatment |
8 |
| Second IVIg course in Guillain-Barre syndrome patients with poor prognosis (SID-GBS trial): Protocol for a double-blind randomized, placebo-controlled clinical trial |
7 |
| Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies |
7 |
| Vinca alkaloids, thalidomide and eribulin-induced peripheral neurotoxicity: From pathogenesis to treatment |
6 |
| Taxane and epothilone-induced peripheral neurotoxicity: From pathogenesis to treatment |
5 |
| Intraneural perineuriomas: diagnostic value of magnetic resonance neurography |
5 |
| Phrenic nerve involvement and respiratory muscle weakness in patients with Charcot-Marie-Tooth disease 1A |
5 |
| International chronic inflammatory demyelinating polyneuropathy outcome study (ICOS): Protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome |
4 |
| Peripheral Neuropathy Research Registry: A prospective cohort |
4 |
| Small heat shock protein B3 (HSPB3) mutation in an axonal Charcot-Marie-Tooth disease family |
4 |
| Clinical relevance of serum antibodies to GD1b in immune-mediated neuropathies |
4 |
| A unified model of the excitability of mouse sensory and motor axons |
4 |
| Clinical factors, diagnostic delay, and residual deficits in chronic inflammatory demyelinating polyradiculoneuropathy |
4 |
| Individualized immunoglobulin therapy in chronic immune-mediated peripheral neuropathies |
4 |
| Peripheral neuropathy in Tangier disease: A literature review and assessment |
4 |
| A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol |
4 |
| Whole-exome sequencing reveals a novel missense mutation in the MARS gene related to a rare Charcot-Marie-Tooth neuropathy type 2U |
4 |
| N-hexane exposure: a cause of small fiber neuropathy |
4 |
| Testing overwork weakness in Charcot-Marie-tooth disease: Is it true or false? |
3 |
| The genetic heterogeneity of hereditary transthyretin amyloidosis in a sample of the Brazilian population |
3 |
| In situ molecular characterization of endoneurial microvessels that form the blood-nerve barrier in normal human adult peripheral nerves |
3 |
| Novel GARS mutation presenting as autosomal dominant intermediate Charcot-Marie-Tooth disease |
3 |
| Differences between acute-onset chronic inflammatory demyelinating polyneuropathy and acute inflammatory demyelinating polyneuropathy in adult patients |
3 |
| Elevated leukocyte count in cerebrospinal fluid of patients with chronic inflammatory demyelinating polyneuropathy |
3 |
| Neuromuscular disease-specific questionnaire to assess quality of life in patients with chronic inflammatory demyelinating polyradiculoneuropathy |
3 |
| Protocol of a dose response trial of IV immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (DRIP study) |
3 |
| Acute flaccid paralysis: Do not forget beriberi neuropathy |
3 |
| ATL3 gene mutation in a Chinese family with hereditary sensory neuropathy type 1F |
3 |
| Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity |
3 |
| Anti-allodynic and anti-inflammatory effects of 17 alpha-hydroxyprogesterone caproate in oxaliplatin-induced peripheral neuropathy |
3 |
| Increased incidence of axonal Guillain-Barre syndrome in La Spezia area of Italy: A 13-year follow-up study |
3 |
| A population-based and cross-sectional study of the long-term prognosis in multifocal motor neuropathy |
2 |
| Genetic epidemiology, demographic, and clinical characteristics of Charcot-Marie-tooth disease in the island of Gran Canaria (Spain) |
2 |
| Changes in intraepidermal nerve fiber and Langerhans cell densities in the plantar skin of rats after mercuric chloride exposure |
2 |
| A mutation in the heptad repeat 2 domain of MFN2 in a large CMT2A family |
2 |
| Nociceptin/orphanin FQ opioid peptide-receptor expression in pachyonychia congenita |
2 |
| A novel SCN9A splicing mutation in a compound heterozygous girl with congenital insensitivity to pain, hyposmia and hypogeusia |
2 |
| The 2016 Singapore Zika virus outbreak did not cause a surge in Guillain-Barre syndrome |
2 |
| Diagnosis and treatment response in the asymmetric variant of chronic inflammatory demyelinating polyneuropathy |
2 |
| POLG mutations presenting as Charcot-Marie-Tooth disease |
2 |
| Clinical and genetic features of Charcot-Marie-Tooth disease 2F and hereditary motor neuropathy 2B in Japan |
2 |
